Impact of the Molecular Characterization Initiative on Pediatric CNS Tumors

Are you looking for molecular characterization data for your pediatric cancer research studies? If so, join this event to learn more about the Molecular Characterization Initiative (MCI)!

Launched in 2022, the Childhood Cancer Data Initiative (CCDI) MCI is a national strategy aimed at facilitating the comprehensive clinical and molecular characterization of childhood cancers at no cost to participants. The MCI, a partnership including the Children’s Oncology Group, provides comprehensive genomic profiling for newly diagnosed central nervous system (CNS) tumors, soft tissue sarcomas, rare tumors, and high-risk neuroblastomas.

Join us for an informative webinar to learn about the MCI and its impact on pediatric CNS tumor research. You’ll hear about:

• the breadth of the genetic and clinical data collected through the MCI and how these data are shaping our understanding of pediatric CNS tumors.
• the clinical impact of the MCI for children with CNS tumors and treating institutions across the United States.
• how MCI data are influencing therapeutic study design, study screening, and the identification of treatment options for pediatric cancer.

This webinar is part of the CCDI webinar series, which highlights how to use CCDI’s web applications, platforms, and data and gives attendees the opportunity to learn how to use available resources.